cIAP1/cIAP2 · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14cIAP1/cIAP2 shows clinical signal disease relevance led by fallopian tube cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q13489. Start with fallopian tube cancer, then reuse UniProt Q13489 as the stable protein anchor across project notes and exports.
Start with fallopian tube cancer, then reuse UniProt Q13489 as the stable protein anchor across project notes and exports.
cIAP1/cIAP2 shows clinical signal disease relevance led by fallopian tube cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with fallopian tube cancer because it currently carries clinical signal support. Linked drugs include BIRINAPANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyBaculoviral IAP repeat-containing protein 3
Review this target as cIAP1/cIAP2, mapped to UniProt Q13489. ChEMBL maps the protein component as Baculoviral IAP repeat-containing protein 3. Sequence length is 604 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats cIAP1/cIAP2 as ChEMBL target CHEMBL3038465, mapped to UniProt Q13489. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether cIAP1/cIAP2 is the right protein anchor across sources, using UniProt Q13489 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why fallopian tube cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | cIAP1/cIAP2 |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | Q13489 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Baculoviral IAP repeat-containing protein 3 |
| UniProt Accession | Q13489 |
| Component Type | Protein |
| Sequence Length | 604 aa |
Baculoviral IAP repeat-containing protein 3
Review this target as cIAP1/cIAP2, mapped to UniProt Q13489. ChEMBL maps the protein component as Baculoviral IAP repeat-containing protein 3. Sequence length is 604 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
cIAP1/cIAP2 shows clinical signal disease relevance led by fallopian tube cancer. 5 more disease programs remain visible in the same review block.
Start review with fallopian tube cancer because it currently carries clinical signal support. Linked drugs include BIRINAPANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |